GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ASLAN Pharmaceuticals Ltd (NAS:ASLN) » Definitions » Net Income (Continuing Operations)

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Net Income (Continuing Operations) : $-35.03 Mil (TTM As of Mar. 2024)


View and export this data going back to 2018. Start your Free Trial

What is ASLAN Pharmaceuticals Net Income (Continuing Operations)?

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. ASLAN Pharmaceuticals's Net Income (Continuing Operations) for the three months ended in Mar. 2024 was $-9.92 Mil. Its Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 was $-35.03 Mil.


ASLAN Pharmaceuticals Net Income (Continuing Operations) Historical Data

The historical data trend for ASLAN Pharmaceuticals's Net Income (Continuing Operations) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ASLAN Pharmaceuticals Net Income (Continuing Operations) Chart

ASLAN Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Income (Continuing Operations)
Get a 7-Day Free Trial Premium Member Only Premium Member Only -47.07 -16.97 -31.59 -51.38 -44.22

ASLAN Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Net Income (Continuing Operations) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -19.11 -1.89 -9.71 -13.51 -9.92

ASLAN Pharmaceuticals Net Income (Continuing Operations) Calculation

Net Income (Continuing Operations) indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period.

Net Income (Continuing Operations) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-35.03 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ASLAN Pharmaceuticals  (NAS:ASLN) Net Income (Continuing Operations) Explanation

Net Income (Continuing Operations) excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.


ASLAN Pharmaceuticals Net Income (Continuing Operations) Related Terms

Thank you for viewing the detailed overview of ASLAN Pharmaceuticals's Net Income (Continuing Operations) provided by GuruFocus.com. Please click on the following links to see related term pages.


ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Business Description

Industry
Traded in Other Exchanges
N/A
Address
3 Temasek Avenue, Level 18, Centennial Tower, Singapore, SGP, 039190
ASLAN Pharmaceuticals Ltd is a clinical-stage immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients. The company is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease.

ASLAN Pharmaceuticals (ASLAN Pharmaceuticals) Headlines

From GuruFocus